Related Experiment Video

Updated: Aug 21, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Role of farnesyltransferase inhibitors in hematologic malignancies

Edgardo S Santos1, Joseph D Rosenblatt, Mark Goodman

  • 1Division of Hematology/Oncology, University of Miami, Sylvester Comprehensive Cancer Center, D8-4, Miami, FL 33136, USA. edgardo_ny@hotmail.com

Expert Review of Anticancer Therapy
|October 16, 2004
PubMed

Insights

Farnesyltransferase inhibitors show promise in treating acute myeloid leukemia (AML) and other blood cancers. These inhibitors target Ras signaling pathways, offering a new therapeutic approach for hematologic malignancies.

Area of Science:

  • Oncology
  • Hematology
  • Molecular Biology

Background:

  • Hematologic malignancies treatment has advanced with new pathway and target molecule discoveries.
  • Ras mutations are implicated in acute leukemia pathogenesis.
  • Farnesyltransferase inhibitors (FTIs) target Ras signaling.

Purpose of the Study:

  • To evaluate the efficacy of FTIs in hematologic malignancies.
  • To explore the role of FTIs in acute myeloid leukemia (AML).
  • To investigate FTI activity in other hematologic disorders.

Main Methods:

  • Early clinical trials of FTIs in patients with hematologic malignancies.
  • Assessment of FTI activity as single agents and in combination therapy.
  • Exploration of FTI use in myelodysplasia, chronic myelogenous leukemia, and multiple myeloma.

Main Results:

  • FTIs demonstrated promise in early trials for acute myeloid leukemia (AML).
  • Responses in AML trials did not consistently correlate with Ras mutations, suggesting other pathways are involved.
  • FTIs showed activity as single agents in poor-risk AML, indicating potential in combination therapy.

Conclusions:

  • FTIs represent a promising new therapeutic strategy for hematologic malignancies.
  • Further investigation of FTIs is warranted in various hematologic cancers, including AML, myelodysplasia, CML, and multiple myeloma.
  • FTIs may play a role in combination therapies for hematologic malignancies.

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...